Intercept Pharma (ICPT) Posts Mixed Q2 Results: Updates on Ocaliva
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Laidlaw Downgrades Intercept Pharmaceuticals (ICPT) to Sell
August 5, 2016 8:46 AM EDT
Laidlaw downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Buy to Sell with a price target of $105, implying downside of 40%. Analyst Jim Molloy lowered expectations for OCA for NASH.
"The company indicated that FY17 operating expenses are likely to be higher than the $360M $400M spend for FY16, and that the uptake of Ocaliva for PBC in the US and the EU should be expected to proceed at a rather moderated pace. The company has ~$850M in cash... More
Intercept (ICPT) OCA Off to Gradual Start in PBC, BMO Capital Notes; PT to $218
August 4, 2016 1:55 PM EDTBMO Capital analyst M. Ian Somaiya trimmed his price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $218.00 (from $219.00) but maintained an Outperform rating following the sell-off following 2Q16 results is primarily driven by a lack of visibility into the timing of meaningful sales for recently... More
